Literature DB >> 7542762

Direct and specific interaction of c-Src with Neu is involved in signaling by the epidermal growth factor receptor.

S K Muthuswamy1, W J Muller.   

Abstract

Transgenic mice expressing either the activated or wild type neu oncogene heritably develop metastatic mammary tumors. Tumor development in this transgenic mouse model correlates with activation of the Neu tyrosine kinase. Recently, we have shown that these Neu-induced mammary tumors possess elevated c-Src tyrosine kinase activity. Here, we demonstrate that c-Src requires tyrosine phosphorylated Neu for its ability to associate with Neu in vivo and this association is likely the result of a direct physical binding of c-Src SH2 domain to the tyrosine phosphorylated Neu. By contrast, the c-Src SH2 domain did not interact directly with tyrosine phosphorylated EGFR. Moreover, in established cell lines expressing elevated levels of EGFR, EGF stimulation results in transphosphorylation of Neu and formation of complexes between c-Src and tyrosine phosphorylated Neu. Taken together, these observations suggest that activation of c-Src by these two closely related EGFR family members results from a direct and specific interaction of c-Src with tyrosine phosphorylated Neu.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7542762

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  23 in total

1.  Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation.

Authors:  D L Dankort; Z Wang; V Blackmore; M F Moran; W J Muller
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

2.  Loss of Hsp90 association up-regulates Src-dependent ErbB2 activity.

Authors:  Wanping Xu; Xitong Yuan; Kristin Beebe; Zhexin Xiang; Len Neckers
Journal:  Mol Cell Biol       Date:  2006-10-09       Impact factor: 4.272

Review 3.  Signal transduction in transgenic mouse models of human breast cancer--implications for human breast cancer.

Authors:  Richard Marcotte; William J Muller
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-07-24       Impact factor: 2.673

4.  Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: implications for human breast cancer.

Authors:  D Dankort; B Maslikowski; N Warner; N Kanno; H Kim; Z Wang; M F Moran; R G Oshima; R D Cardiff; W J Muller
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

5.  Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?

Authors:  Teresa Troiani; Erika Martinelli; Floriana Morgillo; Anna Capasso; Anna Nappi; Vincenzo Sforza; Fortunato Ciardiello
Journal:  Ther Adv Med Oncol       Date:  2013-01       Impact factor: 8.168

6.  ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner.

Authors:  M A Olayioye; D Graus-Porta; R R Beerli; J Rohrer; B Gay; N E Hynes
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

Review 7.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

8.  Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice.

Authors:  W J Muller; C L Arteaga; S K Muthuswamy; P M Siegel; M A Webster; R D Cardiff; K S Meise; F Li; S A Halter; R J Coffey
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

9.  Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab.

Authors:  Deric L Wheeler; Mari Iida; Tim J Kruser; Meghan M Nechrebecki; Emily F Dunn; Eric A Armstrong; Shyhmin Huang; Paul M Harari
Journal:  Cancer Biol Ther       Date:  2009-04-22       Impact factor: 4.742

10.  The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants.

Authors:  B M Chung; M Dimri; M George; A L Reddi; G Chen; V Band; H Band
Journal:  Oncogene       Date:  2009-03-23       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.